PEDIATRIX MEDICAL GROUP INC (MD) Stock Fundamental Analysis
USA - NYSE:MD - US58502B1061 - Common Stock
16.43 USD
+0.25 (+1.55%)
We assign a fundamental rating of 5 out of 10 to MD. MD was compared to 101 industry peers in the Health Care Providers & Services industry. MD has an average financial health and profitability rating. MD may be a bit undervalued, certainly considering the very reasonable score on growth These ratings would make MD suitable for value investing!
1. Profitability
1.1 Basic Checks
MD had positive earnings in the past year.
In the past year MD had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: MD reported negative net income in multiple years.
MD had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
MD has a Return On Assets of 5.23%. This is amongst the best in the industry. MD outperforms 80.20% of its industry peers.
The Return On Equity of MD (13.18%) is better than 81.19% of its industry peers.
MD has a better Return On Invested Capital (9.55%) than 81.19% of its industry peers.
MD had an Average Return On Invested Capital over the past 3 years of 7.83%. This is in line with the industry average of 9.19%.
The last Return On Invested Capital (9.55%) for MD is above the 3 year average (7.83%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.23% | ||
| ROE | 13.18% | ||
| ROIC | 9.55% |
ROA(3y)-1.5%
ROA(5y)-4.7%
ROE(3y)-4.21%
ROE(5y)-20.91%
ROIC(3y)7.83%
ROIC(5y)7.13%
1.3 Margins
The Profit Margin of MD (5.66%) is better than 81.19% of its industry peers.
MD has a Operating Margin of 10.97%. This is amongst the best in the industry. MD outperforms 80.20% of its industry peers.
In the last couple of years the Operating Margin of MD has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.97% | ||
| PM (TTM) | 5.66% | ||
| GM | N/A |
OM growth 3Y-7.13%
OM growth 5Y-6.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
MD has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for MD has been increased compared to 1 year ago.
MD has more shares outstanding than it did 5 years ago.
The debt/assets ratio for MD is higher compared to a year ago.
2.2 Solvency
MD has an Altman-Z score of 1.95. This is not the best score and indicates that MD is in the grey zone with still only limited risk for bankruptcy at the moment.
MD has a Altman-Z score of 1.95. This is comparable to the rest of the industry: MD outperforms 47.52% of its industry peers.
The Debt to FCF ratio of MD is 2.68, which is a good value as it means it would take MD, 2.68 years of fcf income to pay off all of its debts.
MD has a better Debt to FCF ratio (2.68) than 80.20% of its industry peers.
MD has a Debt/Equity ratio of 0.70. This is a neutral value indicating MD is somewhat dependend on debt financing.
The Debt to Equity ratio of MD (0.70) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.7 | ||
| Debt/FCF | 2.68 | ||
| Altman-Z | 1.95 |
ROIC/WACC1.11
WACC8.63%
2.3 Liquidity
A Current Ratio of 1.80 indicates that MD should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.80, MD is in the better half of the industry, outperforming 67.33% of the companies in the same industry.
A Quick Ratio of 1.80 indicates that MD should not have too much problems paying its short term obligations.
With a decent Quick ratio value of 1.80, MD is doing good in the industry, outperforming 68.32% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.8 | ||
| Quick Ratio | 1.8 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 53.39% over the past year.
MD shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -15.01% yearly.
MD shows a decrease in Revenue. In the last year, the revenue decreased by -3.08%.
Measured over the past years, MD shows a small growth in Revenue. The Revenue has been growing by 2.49% on average per year.
EPS 1Y (TTM)53.39%
EPS 3Y-2.95%
EPS 5Y-15.01%
EPS Q2Q%55.88%
Revenue 1Y (TTM)-3.08%
Revenue growth 3Y1.74%
Revenue growth 5Y2.49%
Sales Q2Q%-7.03%
3.2 Future
Based on estimates for the next years, MD will show a small growth in Earnings Per Share. The EPS will grow by 3.76% on average per year.
The Revenue is expected to grow by 2.34% on average over the next years.
EPS Next Y24.34%
EPS Next 2Y12.88%
EPS Next 3Y10.03%
EPS Next 5Y3.76%
Revenue Next Year-5.59%
Revenue Next 2Y-1.54%
Revenue Next 3Y0.03%
Revenue Next 5Y2.34%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 9.08, the valuation of MD can be described as very reasonable.
Compared to the rest of the industry, the Price/Earnings ratio of MD indicates a rather cheap valuation: MD is cheaper than 94.06% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.20, MD is valued rather cheaply.
With a Price/Forward Earnings ratio of 8.65, the valuation of MD can be described as very reasonable.
MD's Price/Forward Earnings ratio is rather cheap when compared to the industry. MD is cheaper than 92.08% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.70, MD is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.08 | ||
| Fwd PE | 8.65 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, MD is valued cheaper than 87.13% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of MD indicates a rather cheap valuation: MD is cheaper than 95.05% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.3 | ||
| EV/EBITDA | 6.52 |
4.3 Compensation for Growth
MD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of MD may justify a higher PE ratio.
PEG (NY)0.37
PEG (5Y)N/A
EPS Next 2Y12.88%
EPS Next 3Y10.03%
5. Dividend
5.1 Amount
No dividends for MD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSE:MD (9/18/2025, 11:48:35 AM)
16.43
+0.25 (+1.55%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners92.49%
Inst Owner Change1.32%
Ins Owners1.88%
Ins Owner Change8.02%
Market Cap1.43B
Analysts78.75
Price Target16.92 (2.98%)
Short Float %2.26%
Short Ratio2.53
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)26.94%
Min EPS beat(2)21.14%
Max EPS beat(2)32.73%
EPS beat(4)4
Avg EPS beat(4)26.19%
Min EPS beat(4)15.9%
Max EPS beat(4)34.96%
EPS beat(8)6
Avg EPS beat(8)10.2%
EPS beat(12)6
Avg EPS beat(12)3.22%
EPS beat(16)9
Avg EPS beat(16)4.71%
Revenue beat(2)0
Avg Revenue beat(2)-1.7%
Min Revenue beat(2)-1.97%
Max Revenue beat(2)-1.44%
Revenue beat(4)1
Avg Revenue beat(4)-0.9%
Min Revenue beat(4)-1.97%
Max Revenue beat(4)0.31%
Revenue beat(8)1
Avg Revenue beat(8)-2.7%
Revenue beat(12)1
Avg Revenue beat(12)-2.84%
Revenue beat(16)2
Avg Revenue beat(16)-2.48%
PT rev (1m)-3.26%
PT rev (3m)-3.26%
EPS NQ rev (1m)1.21%
EPS NQ rev (3m)10.23%
EPS NY rev (1m)8.04%
EPS NY rev (3m)10.45%
Revenue NQ rev (1m)0.12%
Revenue NQ rev (3m)0.57%
Revenue NY rev (1m)0.62%
Revenue NY rev (3m)0.62%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.08 | ||
| Fwd PE | 8.65 | ||
| P/S | 0.74 | ||
| P/FCF | 6.3 | ||
| P/OCF | 5.85 | ||
| P/B | 1.72 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.52 |
EPS(TTM)1.81
EY11.02%
EPS(NY)1.9
Fwd EY11.56%
FCF(TTM)2.61
FCFY15.87%
OCF(TTM)2.81
OCFY17.09%
SpS22.29
BVpS9.57
TBVpS-4.8
PEG (NY)0.37
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.23% | ||
| ROE | 13.18% | ||
| ROCE | 12.09% | ||
| ROIC | 9.55% | ||
| ROICexc | 11.91% | ||
| ROICexgc | 104.6% | ||
| OM | 10.97% | ||
| PM (TTM) | 5.66% | ||
| GM | N/A | ||
| FCFM | 11.7% |
ROA(3y)-1.5%
ROA(5y)-4.7%
ROE(3y)-4.21%
ROE(5y)-20.91%
ROIC(3y)7.83%
ROIC(5y)7.13%
ROICexc(3y)8.94%
ROICexc(5y)8.89%
ROICexgc(3y)78.23%
ROICexgc(5y)75.12%
ROCE(3y)9.91%
ROCE(5y)9.03%
ROICexcg growth 3Y26.95%
ROICexcg growth 5Y24.1%
ROICexc growth 3Y3.64%
ROICexc growth 5Y14.51%
OM growth 3Y-7.13%
OM growth 5Y-6.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.92
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.7 | ||
| Debt/FCF | 2.68 | ||
| Debt/EBITDA | 2.47 | ||
| Cap/Depr | 73.88% | ||
| Cap/Sales | 0.9% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 103.31% | ||
| Profit Quality | 206.51% | ||
| Current Ratio | 1.8 | ||
| Quick Ratio | 1.8 | ||
| Altman-Z | 1.95 |
F-Score7
WACC8.63%
ROIC/WACC1.11
Cap/Depr(3y)81.28%
Cap/Depr(5y)89.11%
Cap/Sales(3y)1.42%
Cap/Sales(5y)1.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)53.39%
EPS 3Y-2.95%
EPS 5Y-15.01%
EPS Q2Q%55.88%
EPS Next Y24.34%
EPS Next 2Y12.88%
EPS Next 3Y10.03%
EPS Next 5Y3.76%
Revenue 1Y (TTM)-3.08%
Revenue growth 3Y1.74%
Revenue growth 5Y2.49%
Sales Q2Q%-7.03%
Revenue Next Year-5.59%
Revenue Next 2Y-1.54%
Revenue Next 3Y0.03%
Revenue Next 5Y2.34%
EBIT growth 1Y39.69%
EBIT growth 3Y-5.51%
EBIT growth 5Y-4.62%
EBIT Next Year41.46%
EBIT Next 3Y15.15%
EBIT Next 5YN/A
FCF growth 1Y63.28%
FCF growth 3Y60.68%
FCF growth 5Y-11.42%
OCF growth 1Y43.72%
OCF growth 3Y39.11%
OCF growth 5Y-10.4%